Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia Capital and Sabby Capital Are Bullish on These Stocks

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds’ bullishness. Not only did Steve Cohen’s Point72 Asset Management disclose an increase in its exposure to the company today, but also Matt Sirovich and Jeremy Mindich’s Scopia Capital did so. According to a Schedule 13G filing, the fund upped its bet by 23.6%, and now owns 5.17 million shares of Common Stock, which account for 17.52% of the Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s shares outstanding. Also today, Hal Mintz’s Sabby Capital more than quadrupled its exposure to Cytori Therapeutics Inc (NASDAQ:CYTX), and now owns 8.39 million shares of Common Stock, which represent 9.99% of the company’s outstanding stock.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is an $865.5 million market cap biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As I mentioned above, two major institutional investors disclosed boosts in their stakes today: Scopia Capital and Point72 Asset Management. Both these purchases came amidst a low prices environment. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) plummeted more than 56% year-to-date, opening an attractive entry point for long-term investors betting on growth. In fact, analysts expect the company to enormously outperform its peers over the mid and long-term, both in terms of EPS growth and stock price.

In addition to these two funds, which are the largest institutional shareholder in the company, amongst those we track, Kevin Kotler’s Broadfin Capital last disclosed having more than doubled its wage on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), to 810,044 shares.

Cytori Therapeutics Inc (NASDAQ:CYTX) is a $39.5 million market cap company engaged in the development of novel treatments for cardiovascular diseases and soft tissue injuries and burns. According to its most recent SEC filing, Sabby Capital added about 6.6 million shares to its holdings in the company, and now owns about 8.39 million shares of Common Stock.

This makes of Hal Mintz’s fund the largest institutional shareholder in the company (amongst those we track) by far. Sabby Capital is trailed by Phill Gross and Robert Atchinson’s Adage Capital Management, which last declared ownership of 124,911 shares of Cytori Therapeutics Inc (NASDAQ:CYTX).

Cytori Therapeutics Inc (NASDAQ:CYTX) has been performing ever worse than Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). The stock lost about 80% year-to-date, opening, once again, a very attractive entry point for long-term investors.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!